<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01845025</url>
  </required_header>
  <id_info>
    <org_study_id>CFOR258D2416</org_study_id>
    <secondary_id>2012-004854-27</secondary_id>
    <nct_id>NCT01845025</nct_id>
  </id_info>
  <brief_title>Study of Safety of Foradil in Patients With Persistent Asthma</brief_title>
  <official_title>A 26 Week, Randomized, Active-controlled Safety Study of Double-blind Formoterol Fumarate in Free Combination With an Inhaled Corticosteroid Versus an Inhaled Corticosteroid in Adolescent and Adult Patients With Persistent Asthma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to assess whether the risk of serious asthma-related events
      (asthma-related hospitalizations, asthma related intubations, and asthma related deaths) in
      adolescents and adults (12 years of age and older) taking inhaled formoterol
      fumarate/fluticasone propionate combination was the same as those taking inhaled fluticasone
      propionate alone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a 26 week, double blind, randomized, active-controlled safety study of Foradil in
      free combination with inhaled corticosteroid versus an inhaled corticosteroid alone in adults
      and adolescent patients with persistent asthma. The primary objective of the study was to
      demonstrate that the addition of formoterol fumarate to fluticasone propionate is
      non-inferior to fluticasone propionate alone in terms of the risk of composite serious asthma
      related events (asthma-related hospitalization, asthma-related intubation, and asthma-related
      death). The individual components of the composite primary endpoint (i.e., asthma-related
      hospitalization, asthma-related intubation and asthma-related death) will be assessed as a
      secondary safety endpoints.

      The efficacy assessment is the secondary objective.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Due to the action to withdraw the Foradil Aerolizer NDA in US; study was discontinued. This was
    a commercial reason and not due to any change in benefit-risk.
  </why_stopped>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of First Occurrence(s) of Any Composite Endpoint Including Asthma-related Hospitalizations, Intubations and Deaths During the Study at 26 Weeks</measure>
    <time_frame>26 weeks</time_frame>
    <description>The primary safety endpoint was the number of first occurrence(s) of any composite endpoint. The composite events include asthma-related deaths, asthma-related intubations and asthma-related hospitalizations. The number of events includes all adjudication confirmed events, one patient could experience multiple events during the course of study; Event rate = 100 * n patients with any events / total N patients in treatment group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Asthma Exacerbations at 26 Weeks</measure>
    <time_frame>26 weeks</time_frame>
    <description>Number of asthma exacerbations events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Days of School/Work Missed at 26 Weeks</measure>
    <time_frame>26 weeks</time_frame>
    <description>The percentage of days of school/work missed during the treatment period (26 weeks). Overall percentage of school days missed for each student patient or of work days missed is calculated by total number of days missed divided by total days of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Days With Limited Ability to Perform Normal Daily Activities at 26 Weeks</measure>
    <time_frame>26 weeks</time_frame>
    <description>The percentage of days with limited ability to perform normal daily activities during the treatment period (26 weeks). Percentage is calculated as total number of days when the patient had limited ability to perform normal daily activities divided by total days of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Days With Nighttime Awakenings at 26 Weeks</measure>
    <time_frame>26 weeks</time_frame>
    <description>Percentage of days with nighttime awakenings during the treatment period (26 weeks)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Days With no Rescue Medication Use at 26 Weeks</measure>
    <time_frame>26 weeks</time_frame>
    <description>Percentage of rescue free days is calculated as total number of days with no rescue medication was taken divided by total days of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Days With no Symptoms at 26 Weeks</measure>
    <time_frame>26 weeks</time_frame>
    <description>Percentage of days with no symptoms during the treatment period (26 weeks). Percentage is calculated as total number of days with no symptoms divided by total days of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Asthma Control Questionnaire (ACQ - 6) Total Score at Week 26</measure>
    <time_frame>baseline and 26 weeks</time_frame>
    <description>Change from baseline in Asthma control Questionnaire (ACQ - 6) total score at week 26. Results of the Asthma control questionnaire (ACQ-6); The average score of the six questions is calculated as the sum of scores divided by the number of questions that were answered at the time point, as long as there were at least 4 questions answered. The ACQ6 score is calculated as the mean of the responses to the first 6 questions of the ACQ. The ACQ is a scale containing 7 questions, each question has a 7-point scale which ranges from 0 to 6; a total score of 0 corresponds to no impairment and a total score of 6 corresponds to maximum impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unplanned Healthcare Utilization at Visit 3 (Week 4), Visit 4 (Week 12) and Visit 5 (Week 26)</measure>
    <time_frame>Week 4, Week 12, and Week 26</time_frame>
    <description>Unplanned healthcare utilization by visit (Telephone contact with study doctor (MD); Telephone contact with other physician (MD) or healthcare provider (HCP); Unscheduled or unplanned visit to study doctor (including home visits); Unscheduled or unplanned visit to other physician or healthcare provider (including home visits); Emergency department or hospital visit (&lt; 24 hours); Hospital admission or Emergency department visit (&gt; 24 hours).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">827</enrollment>
  <condition>Persistent Asthma</condition>
  <arm_group>
    <arm_group_label>FOM 12 mcg + FP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Formoterol 12 mcg + fluticasone propionate 100 mcg, 250 mcg or 500 mcg for inhalation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>fluticasone propionate (FP)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>fluticasone propionate 100 mcg, 250 mcg or 500 mcg + Placebo to Match Formoterol 12 mcg for inhalation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formoterol 12 mcg</intervention_name>
    <description>Formoterol 12 mcg one inhalation twice daily, via dry powder inhaler</description>
    <arm_group_label>FOM 12 mcg + FP</arm_group_label>
    <other_name>FOR258</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluticasone propionate 100 mcg</intervention_name>
    <description>Fluticasone propionate 100 mcg one inhalation twice daily via dry powder inhaler</description>
    <arm_group_label>FOM 12 mcg + FP</arm_group_label>
    <arm_group_label>fluticasone propionate (FP)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluticasone propionate 250 mcg</intervention_name>
    <description>Fluticasone propionate 250 mcg one inhalation twice daily via dry powder inhaler</description>
    <arm_group_label>FOM 12 mcg + FP</arm_group_label>
    <arm_group_label>fluticasone propionate (FP)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluticasone propionate 500 mcg</intervention_name>
    <description>Fluticasone propionate 500 mcg, one inhalation twice daily via dry powder inhaler</description>
    <arm_group_label>FOM 12 mcg + FP</arm_group_label>
    <arm_group_label>fluticasone propionate (FP)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to match formoterol one inhalation twice daily via dry powder inhaler</description>
    <arm_group_label>fluticasone propionate (FP)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Written informed consent, and assent if applicable, must be obtained before any
             assessment is performed.

          2. Male or female patients 12 years of age and older

          3. Confirmed diagnosis of persistent asthma, as defined by national and international
             asthma guidelines (e.g., GINA; NIH; etc.) for at least 1 year prior to study
             enrollment.

          4. PEF≥50% of predicted normal value.

          5. Current and appropriate use of one of the treatments listed in the protocol for
             asthma.

          6. Recent asthma exacerbation between 30 days and 12 months prior to randomization that
             either:

               -  required treatment with systemic corticosteroids (tablets, suspension, or
                  injection) or

               -  required hospitalization (defined as an inpatient stay or &gt;24-hour stay in an
                  observation area in an emergency room or other equivalent facility)

        Key Exclusion Criteria:

          1. History of life-threatening asthma episode that required intubation and/or was
             associated with hypercapnia requiring non-invasive ventilatory support.

          2. Current evidence of pneumonia, pneumothorax, atelectasis, pulmonary fibrotic disease,
             allergic bronchopulmonary aspergillosis, cystic fibrosis, bronchopulmonary dysplasia,
             or other respiratory abnormalities other than asthma.

          3. Current evidence of, or past physician assessment of, chronic bronchitis, emphysema,
             or chronic obstructive pulmonary disease.

          4. History of smoking ≥ 10 pack years.

          5. Exercise induced asthma (as the only asthma-related diagnosis) not requiring daily
             asthma control medicine.

          6. Suspected or documented bacterial or viral infection of the upper or lower respiratory
             tract, sinus or middle ear that is not resolved at randomization.

          7. Worsening/Unstable asthma within 7 days prior to randomization.

          8. Any asthma exacerbation requiring systemic corticosteroids within 30 days of
             randomization or more than 4 separate exacerbations in the 12 months preceding
             randomization.

          9. Two or more hospitalizations for greater than 24 hours duration for treatment of
             asthma in the 12 months preceding randomization.

         10. History of hypersensitivity to any beta2-agonist, sympathomimetic drug, inhaled
             corticosteroids, or systemic corticosteroid therapy or any component of the possible
             study treatments in this trial, including severe milk protein hypersensitivity.

         11. Use of anti-IgE (e.g., omalizumab) or any other monoclonal antibody, in the 6 months
             prior to randomization.

         12. Use of (Beta) β-blockers within 1 day prior to first dose of study medication.

         13. Use of ICS, LABA, ICS+LABA, LTRAs, leukotriene modifiers, anticholinergics, or
             theophylline must be discontinued prior to the first dose of investigational
             treatment.

         14. Use of a potent CYP3A4 inhibitor within 4 weeks of randomization (e.g., ritonavir,
             atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir,
             saquinavir, ketoconazole, telithromycin).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chrsitopher Compton</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Avondale</city>
        <state>Arizona</state>
        <zip>85323</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>North Hollywood</city>
        <state>California</state>
        <zip>91606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Conyers</city>
        <state>Georgia</state>
        <zip>30012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Stone Mountain</city>
        <state>Georgia</state>
        <zip>30083</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Covington</city>
        <state>Louisiana</state>
        <zip>70433</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gaithersburg</city>
        <state>Maryland</state>
        <zip>20878</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Picayune</city>
        <state>Mississippi</state>
        <zip>39466</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>North Massapequa</city>
        <state>New York</state>
        <zip>11758</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Elizabeth City</city>
        <state>North Carolina</state>
        <zip>27909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Winston Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oaks</city>
        <state>Pennsylvania</state>
        <zip>19456</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>East Greenwich</city>
        <state>Rhode Island</state>
        <zip>02818</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint George</city>
        <state>Utah</state>
        <zip>84790</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mequon</city>
        <state>Wisconsin</state>
        <zip>53092</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53172</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 22, 2013</study_first_submitted>
  <study_first_submitted_qc>April 29, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2013</study_first_posted>
  <results_first_submitted>November 10, 2016</results_first_submitted>
  <results_first_submitted_qc>January 30, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 21, 2017</results_first_posted>
  <last_update_submitted>January 30, 2017</last_update_submitted>
  <last_update_submitted_qc>January 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>formoterol fumarate</keyword>
  <keyword>Foradil</keyword>
  <keyword>inhaled corticosteroid</keyword>
  <keyword>fluticasone propionate</keyword>
  <keyword>safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Formoterol Fumarate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Following the decision to stop further enrollment into the study, 1121 patients had been screened, of whom 825 were randomized. Of the 820 patients randomized and treated and part of Intent To Treat (ITT analysis) 5 patients were randomized but were excluded from the ITT analyses as they did not take study medication.</recruitment_details>
      <pre_assignment_details>827 actual in the protocol section came from the IRT because 2 patients were randomized twice but only counted once.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>FOM 12 mcg + FP</title>
          <description>Formoterol 12 mcg + fluticasone propionate 100 mcg, 250 mcg or 500 mcg for inhalation</description>
        </group>
        <group group_id="P2">
          <title>Fluticasone Propionate (FP)</title>
          <description>fluticasone propionate 100 mcg, 250 mcg or 500 mcg + Placebo to Match Formoterol 12 mcg for inhalation</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="411"/>
                <participants group_id="P2" count="409"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="326"/>
                <participants group_id="P2" count="332"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="85"/>
                <participants group_id="P2" count="77"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unsatisfactory therapeutic effect</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="44"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative problems</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol deviation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missing</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>FOM 12 mcg + FP</title>
          <description>Formoterol 12 mcg + fluticasone propionate 100 mcg, 250 mcg or 500 mcg for inhalation</description>
        </group>
        <group group_id="B2">
          <title>Fluticasone Propionate (FP)</title>
          <description>fluticasone propionate 100 mcg, 250 mcg or 500 mcg + Placebo to Match Formoterol 12 mcg for inhalation</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="411"/>
            <count group_id="B2" value="409"/>
            <count group_id="B3" value="820"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.7" spread="16.67"/>
                    <measurement group_id="B2" value="45.6" spread="17.02"/>
                    <measurement group_id="B3" value="45.2" spread="16.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="284"/>
                    <measurement group_id="B2" value="272"/>
                    <measurement group_id="B3" value="556"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="127"/>
                    <measurement group_id="B2" value="137"/>
                    <measurement group_id="B3" value="264"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of First Occurrence(s) of Any Composite Endpoint Including Asthma-related Hospitalizations, Intubations and Deaths During the Study at 26 Weeks</title>
        <description>The primary safety endpoint was the number of first occurrence(s) of any composite endpoint. The composite events include asthma-related deaths, asthma-related intubations and asthma-related hospitalizations. The number of events includes all adjudication confirmed events, one patient could experience multiple events during the course of study; Event rate = 100 * n patients with any events / total N patients in treatment group.</description>
        <time_frame>26 weeks</time_frame>
        <population>Intent to treat (ITT) population included all randomized patients who took at least one dose (one inhalation) of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>FOM 12 mcg + FP</title>
            <description>Formoterol 12 mcg + fluticasone propionate 100 mcg, 250 mcg or 500 mcg for inhalation</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone Propionate (FP)</title>
            <description>fluticasone propionate 100 mcg, 250 mcg or 500 mcg + Placebo to Match Formoterol 12 mcg for inhalation</description>
          </group>
        </group_list>
        <measure>
          <title>Number of First Occurrence(s) of Any Composite Endpoint Including Asthma-related Hospitalizations, Intubations and Deaths During the Study at 26 Weeks</title>
          <description>The primary safety endpoint was the number of first occurrence(s) of any composite endpoint. The composite events include asthma-related deaths, asthma-related intubations and asthma-related hospitalizations. The number of events includes all adjudication confirmed events, one patient could experience multiple events during the course of study; Event rate = 100 * n patients with any events / total N patients in treatment group.</description>
          <population>Intent to treat (ITT) population included all randomized patients who took at least one dose (one inhalation) of study medication</population>
          <units>number of occurences</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="411"/>
                <count group_id="O2" value="409"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Composite event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asthma-related death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asthma-related intubation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asthma-related hospitalization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Asthma Exacerbations at 26 Weeks</title>
        <description>Number of asthma exacerbations events</description>
        <time_frame>26 weeks</time_frame>
        <population>Intent to treat (ITT) population included all randomized patients who took at least one dose (one inhalation) of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>FOM 12 mcg + FP</title>
            <description>Formoterol 12 mcg + fluticasone propionate 100 mcg, 250 mcg or 500 mcg for inhalation</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone Propionate (FP)</title>
            <description>fluticasone propionate 100 mcg, 250 mcg or 500 mcg + Placebo to Match Formoterol 12 mcg for inhalation</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Asthma Exacerbations at 26 Weeks</title>
          <description>Number of asthma exacerbations events</description>
          <population>Intent to treat (ITT) population included all randomized patients who took at least one dose (one inhalation) of study medication</population>
          <units>events</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="411"/>
                <count group_id="O2" value="409"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="0.62"/>
                    <measurement group_id="O2" value="1.2" spread="0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Days of School/Work Missed at 26 Weeks</title>
        <description>The percentage of days of school/work missed during the treatment period (26 weeks). Overall percentage of school days missed for each student patient or of work days missed is calculated by total number of days missed divided by total days of treatment.</description>
        <time_frame>26 weeks</time_frame>
        <population>Intent to treat (ITT) population included all randomized patients who took at least one dose (one inhalation) of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>FOM 12 mcg + FP</title>
            <description>Formoterol 12 mcg + fluticasone propionate 100 mcg, 250 mcg or 500 mcg for inhalation</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone Propionate (FP)</title>
            <description>fluticasone propionate 100 mcg, 250 mcg or 500 mcg + Placebo to Match Formoterol 12 mcg for inhalation</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Days of School/Work Missed at 26 Weeks</title>
          <description>The percentage of days of school/work missed during the treatment period (26 weeks). Overall percentage of school days missed for each student patient or of work days missed is calculated by total number of days missed divided by total days of treatment.</description>
          <population>Intent to treat (ITT) population included all randomized patients who took at least one dose (one inhalation) of study medication</population>
          <units>percentage of days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="411"/>
                <count group_id="O2" value="409"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.97" spread="4.558"/>
                    <measurement group_id="O2" value="0.56" spread="1.641"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Days With Limited Ability to Perform Normal Daily Activities at 26 Weeks</title>
        <description>The percentage of days with limited ability to perform normal daily activities during the treatment period (26 weeks). Percentage is calculated as total number of days when the patient had limited ability to perform normal daily activities divided by total days of treatment.</description>
        <time_frame>26 weeks</time_frame>
        <population>Intent to treat (ITT) population included all randomized patients who took at least one dose (one inhalation) of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>FOM 12 mcg + FP</title>
            <description>Formoterol 12 mcg + fluticasone propionate 100 mcg, 250 mcg or 500 mcg for inhalation</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone Propionate (FP)</title>
            <description>fluticasone propionate 100 mcg, 250 mcg or 500 mcg + Placebo to Match Formoterol 12 mcg for inhalation</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Days With Limited Ability to Perform Normal Daily Activities at 26 Weeks</title>
          <description>The percentage of days with limited ability to perform normal daily activities during the treatment period (26 weeks). Percentage is calculated as total number of days when the patient had limited ability to perform normal daily activities divided by total days of treatment.</description>
          <population>Intent to treat (ITT) population included all randomized patients who took at least one dose (one inhalation) of study medication</population>
          <units>percentage of days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="411"/>
                <count group_id="O2" value="409"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.73" spread="12.774"/>
                    <measurement group_id="O2" value="4.75" spread="12.705"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Days With Nighttime Awakenings at 26 Weeks</title>
        <description>Percentage of days with nighttime awakenings during the treatment period (26 weeks)</description>
        <time_frame>26 weeks</time_frame>
        <population>Intent to treat (ITT) population included all randomized patients who took at least one dose (one inhalation) of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>FOM 12 mcg + FP</title>
            <description>Formoterol 12 mcg + fluticasone propionate 100 mcg, 250 mcg or 500 mcg for inhalation</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone Propionate (FP)</title>
            <description>fluticasone propionate 100 mcg, 250 mcg or 500 mcg + Placebo to Match Formoterol 12 mcg for inhalation</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Days With Nighttime Awakenings at 26 Weeks</title>
          <description>Percentage of days with nighttime awakenings during the treatment period (26 weeks)</description>
          <population>Intent to treat (ITT) population included all randomized patients who took at least one dose (one inhalation) of study medication</population>
          <units>percentage of days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="411"/>
                <count group_id="O2" value="409"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.55" spread="9.577"/>
                    <measurement group_id="O2" value="4.20" spread="8.956"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Days With no Rescue Medication Use at 26 Weeks</title>
        <description>Percentage of rescue free days is calculated as total number of days with no rescue medication was taken divided by total days of treatment.</description>
        <time_frame>26 weeks</time_frame>
        <population>Intent to treat (ITT) population included all randomized patients who took at least one dose (one inhalation) of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>FOM 12 mcg + FP</title>
            <description>Formoterol 12 mcg + fluticasone propionate 100 mcg, 250 mcg or 500 mcg for inhalation</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone Propionate (FP)</title>
            <description>fluticasone propionate 100 mcg, 250 mcg or 500 mcg + Placebo to Match Formoterol 12 mcg for inhalation</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Days With no Rescue Medication Use at 26 Weeks</title>
          <description>Percentage of rescue free days is calculated as total number of days with no rescue medication was taken divided by total days of treatment.</description>
          <population>Intent to treat (ITT) population included all randomized patients who took at least one dose (one inhalation) of study medication</population>
          <units>percentage of days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="411"/>
                <count group_id="O2" value="409"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.97" spread="27.255"/>
                    <measurement group_id="O2" value="73.29" spread="30.640"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Days With no Symptoms at 26 Weeks</title>
        <description>Percentage of days with no symptoms during the treatment period (26 weeks). Percentage is calculated as total number of days with no symptoms divided by total days of treatment.</description>
        <time_frame>26 weeks</time_frame>
        <population>Intent to treat (ITT) population included all randomized patients who took at least one dose (one inhalation) of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>FOM 12 mcg + FP</title>
            <description>Formoterol 12 mcg + fluticasone propionate 100 mcg, 250 mcg or 500 mcg for inhalation</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone Propionate (FP)</title>
            <description>fluticasone propionate 100 mcg, 250 mcg or 500 mcg + Placebo to Match Formoterol 12 mcg for inhalation</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Days With no Symptoms at 26 Weeks</title>
          <description>Percentage of days with no symptoms during the treatment period (26 weeks). Percentage is calculated as total number of days with no symptoms divided by total days of treatment.</description>
          <population>Intent to treat (ITT) population included all randomized patients who took at least one dose (one inhalation) of study medication</population>
          <units>percentage of days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="411"/>
                <count group_id="O2" value="409"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.47" spread="25.501"/>
                    <measurement group_id="O2" value="77.64" spread="28.394"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Asthma Control Questionnaire (ACQ – 6) Total Score at Week 26</title>
        <description>Change from baseline in Asthma control Questionnaire (ACQ – 6) total score at week 26. Results of the Asthma control questionnaire (ACQ-6); The average score of the six questions is calculated as the sum of scores divided by the number of questions that were answered at the time point, as long as there were at least 4 questions answered. The ACQ6 score is calculated as the mean of the responses to the first 6 questions of the ACQ. The ACQ is a scale containing 7 questions, each question has a 7-point scale which ranges from 0 to 6; a total score of 0 corresponds to no impairment and a total score of 6 corresponds to maximum impairment.</description>
        <time_frame>baseline and 26 weeks</time_frame>
        <population>Intent to treat (ITT) population included all randomized patients who took at least one dose (one inhalation) of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>FOM 12 mcg + FP</title>
            <description>Formoterol 12 mcg + fluticasone propionate 100 mcg, 250 mcg or 500 mcg for inhalation</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone Propionate (FP)</title>
            <description>fluticasone propionate 100 mcg, 250 mcg or 500 mcg + Placebo to Match Formoterol 12 mcg for inhalation</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Asthma Control Questionnaire (ACQ – 6) Total Score at Week 26</title>
          <description>Change from baseline in Asthma control Questionnaire (ACQ – 6) total score at week 26. Results of the Asthma control questionnaire (ACQ-6); The average score of the six questions is calculated as the sum of scores divided by the number of questions that were answered at the time point, as long as there were at least 4 questions answered. The ACQ6 score is calculated as the mean of the responses to the first 6 questions of the ACQ. The ACQ is a scale containing 7 questions, each question has a 7-point scale which ranges from 0 to 6; a total score of 0 corresponds to no impairment and a total score of 6 corresponds to maximum impairment.</description>
          <population>Intent to treat (ITT) population included all randomized patients who took at least one dose (one inhalation) of study medication</population>
          <units>total score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="411"/>
                <count group_id="O2" value="409"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.65" spread="1.224"/>
                    <measurement group_id="O2" value="-0.59" spread="1.094"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Unplanned Healthcare Utilization at Visit 3 (Week 4), Visit 4 (Week 12) and Visit 5 (Week 26)</title>
        <description>Unplanned healthcare utilization by visit (Telephone contact with study doctor (MD); Telephone contact with other physician (MD) or healthcare provider (HCP); Unscheduled or unplanned visit to study doctor (including home visits); Unscheduled or unplanned visit to other physician or healthcare provider (including home visits); Emergency department or hospital visit (&lt; 24 hours); Hospital admission or Emergency department visit (&gt; 24 hours).</description>
        <time_frame>Week 4, Week 12, and Week 26</time_frame>
        <population>Intent to treat (ITT) population included all randomized patients who took at least one dose (one inhalation) of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>FOM 12 mcg + FP</title>
            <description>Formoterol 12 mcg + fluticasone propionate 100 mcg, 250 mcg or 500 mcg for inhalation</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone Propionate (FP)</title>
            <description>fluticasone propionate 100 mcg, 250 mcg or 500 mcg + Placebo to Match Formoterol 12 mcg for inhalation</description>
          </group>
        </group_list>
        <measure>
          <title>Unplanned Healthcare Utilization at Visit 3 (Week 4), Visit 4 (Week 12) and Visit 5 (Week 26)</title>
          <description>Unplanned healthcare utilization by visit (Telephone contact with study doctor (MD); Telephone contact with other physician (MD) or healthcare provider (HCP); Unscheduled or unplanned visit to study doctor (including home visits); Unscheduled or unplanned visit to other physician or healthcare provider (including home visits); Emergency department or hospital visit (&lt; 24 hours); Hospital admission or Emergency department visit (&gt; 24 hours).</description>
          <population>Intent to treat (ITT) population included all randomized patients who took at least one dose (one inhalation) of study medication</population>
          <units>unplanned visits</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="411"/>
                <count group_id="O2" value="409"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Telephone contact with study MD: V3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Telephone contact with other MD or HCP: V3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>unplanned visit to study MD;include home:V3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>unplanned visit to other MD or HCP incl.home:V3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emergency or hospital visit (&lt; 24 hours):V3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hospital admission or Emergency visit (&gt;24hrs):V3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Telephone contact with study MD: V4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Telephone contact with other MD or HCP: V4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>unplanned visit to study MD;include home:V4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>unplanned visit to other MD or HCP incl.home:V4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emergency or hospital visit (&lt; 24 hours):V4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hospital admission or Emergency visit (&gt;24hrs):V4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Telephone contact with study MD: V5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Telephone contact with other MD or HCP: V5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>unplanned visit to study MD;include home:V5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>unplanned visit to other MD or HCP incl.home:V5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emergency or hospital visit (&lt; 24 hours):V5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hospital admission or Emergency visit (&gt;24hrs):V5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>FOM 12 mcg + FP</title>
          <description>Formoterol 12 mcg + fluticasone propionate 100 mcg, 250 mcg or 500 mcg for inhalation</description>
        </group>
        <group group_id="E2">
          <title>Fluticasone Propionate (FP)</title>
          <description>fluticasone propionate 100 mcg, 250 mcg or 500 mcg + Placebo to Match Formoterol 12 mcg for inhalation</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Alcohol poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Dyskinesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="409"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="409"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

